![]() | |
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C10H11N4O7P |
Molar mass | 330.193 g·mol−1 |
3D model ( JSmol) | |
| |
|
Becampanel ( INN) (code name AMP397) is a quinoxalinedione derivative drug which acts as a competitive antagonist of the AMPA receptor ( IC50 = 11 nM). [1] [2] [3] [4] It was investigated as an anticonvulsant for the treatment of epilepsy by Novartis, and was also looked at as a potential treatment for neuropathic pain and cerebral ischemia, but never completed clinical trials. [1] [2] [3] [5]
![]() | |
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C10H11N4O7P |
Molar mass | 330.193 g·mol−1 |
3D model ( JSmol) | |
| |
|
Becampanel ( INN) (code name AMP397) is a quinoxalinedione derivative drug which acts as a competitive antagonist of the AMPA receptor ( IC50 = 11 nM). [1] [2] [3] [4] It was investigated as an anticonvulsant for the treatment of epilepsy by Novartis, and was also looked at as a potential treatment for neuropathic pain and cerebral ischemia, but never completed clinical trials. [1] [2] [3] [5]